week 36 check-in — 6kg down, sulphur burps manageable, one thing confusing me
week 36 check-in — 6kg down, sulphur burps manageable, one thing confusing me, and the part I actually want to talk about is at the bottom.
Since the title puts numbers in the shop window: week 36 and 6kg.
Went 10 to 12.5 on the calendar and had the worst fortnight of the whole run. Dropped back to 10 and everything settled.
28kg over 59 weeks, never went past 10mg, and nausea stayed mild the whole way. Posting because the loud threads are all 15mg.
Sceptical readings welcome. The confident ones are the ones I distrust.
best — the order this archive was captured in
On comparing yourself with the trial number.
SURMOUNT-1 reported roughly 21% mean body weight change at 72 weeks on the highest arm. Three things get dropped every time that figure is quoted here. It is a mean, and the distribution around it is very wide. It is 72 weeks, which is a year and a half. And it is a trial population with trial support, which is not the same as a person with a spreadsheet.
Use it as a rough shape, not a benchmark. A 12% year is inside the ordinary range and people quit over it every week on this board.
Left up, flair changed to Discussion. It is an opinion post and that is fine as long as it is labelled.
On comparing yourself with the trial number.
This. The step interval is a floor, and reading it as a timetable is the most expensive mistake in the thread.
What step are you on and how long have you been there?
Does food noise follow the day after the shot, or is it spread across the week?
Switching from semaglutide, since three people asked in this thread alone.
There is no published dose equivalence between the two. The conversion tables that circulate are somebody’s arithmetic, not data. What people report here is that the first month after a switch is often flat, that the appetite effect feels differently shaped rather than simply stronger, and that starting at the bottom of the ladder again is the common approach.
None of that is a recommendation. It is what the threads say, and the threads are not a clinic.
The 21% figure is a 72-week mean on the highest arm. Quoting it as what someone should expect by week 86 is not a fair reading.
Appetite effect for me is flat across seven days. On sema it was a wave. Same person, different molecule.
Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme. They are different endpoints and the numbers do not transfer.
the four-week step schedule is the label, not folklore
Weekly dosing again, half-life in the same neighbourhood as sema, so a step change takes about a month to reach steady state. Judging a new step at day five is judging noise.
Careful with "everyone tolerates it better". The people it did not suit stop posting, which makes this board look calmer than the drug is.
Disagree with the conversion table. There is no validated equivalence between the two molecules and posting one as though there is does real damage.
week 6 is early to draw any conclusion at all
2.5 is the starter dose and it is not meant to be the dose that works
2.5mg is a four-week starting dose, not a maintenance dose. Worth being precise since people search these threads.
a lot of people plateau nicely at 10mg and never need 15
The step schedule question, answered properly, because it comes up weekly.
The label sets a minimum interval of four weeks between increases. That is a floor on how fast you may go, and it exists because tolerability, not efficacy, is what limits most people. There is nothing in the pharmacology that says you must increase at four weeks, or at eight, or ever.
What decides it in practice is whether the effect you want is still there. If appetite is quiet and the trend is going the right way, the dose is doing its job. If both have genuinely gone flat for six weeks or more, that is a conversation worth having with someone who knows your history.
switching from sema is not a dose conversion, there is no clean equivalence
dual agonist, so the GIP arm is doing something the sema threads will not tell you about
Week 42 was the first time the scale moved after a five-week stall. I changed nothing in that window.
It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.
It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads.
Saving this one. It is the clearest statement of the stall problem I have read here.
SURMOUNT-1 landed around 21% at 72 weeks on the top arm
[removed by moderator]
Correction to my own post above — I said 10mg and I have been on 2.5mg since the spring. Same argument, wrong number.
That percentage is body weight change, not body fat. Different measurement, and the distinction gets lost every time.
Research-use-only material is not approved for human use. Anything in this thread about how a research vial "should" titrate is a discussion about chemistry, not a plan.
sulphur burps are the signature complaint and they are not dangerous
- 1It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part…8 comments in this branch · started by u/elin_ferrari
- 2week 6 is early to draw any conclusion at all7 comments in this branch · started by u/gustav_vermeulen